Gilead Sciences is a biopharmaceutical company that focuses on the research, development, and commercialization of innovative therapeutics to address significant unmet medical needs, particularly in the fields of antiviral therapies, oncology, and inflammation. The company is well-known for its advancements in treatments for diseases such as HIV, hepatitis C, and influenza, while also expanding its portfolio to include oncology products and therapies for other serious conditions. Gilead is committed to improving patient outcomes through its cutting-edge science and collaborative efforts, working to develop medicines that have both transformative efficacy and address critical health challenges on a global scale.
Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its fourth quarter and full year 2024 financial results and 2025 guidance will be released on Tuesday, February 11, 2025, after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s fourth quarter and full year 2024 financial results and provide a business update.
PALM BEACH, Fla., Jan. 22, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The demand for effective pancreatic cancer treatments is and has been undeniably high. The growing number of diagnoses, with the aggressive nature of the disease, fuels the market. This demand is further amplified by rising awareness and a focus on personalized medicine, leading to potentially more targeted and effective therapies. Pancreatic cancer remains a formidable foe, with the American Cancer Society estimating over 66,000 new diagnoses and a staggering 51,750 deaths in the US alone for 2024. This translates to 3% of all cancers and a grim 7% of all cancer fatalities, highlighting the urgent need for improved treatment options. The pancreatic cancer treatment market is driven by several factors, including the rising prevalence of obesity, alcohol consumption, and smoking. These lifestyle factors, combined with the growing geriatric population, are expected to fuel market growth. Additionally, personal or family history of pancreatitis and BRCA2 mutation predisposes individuals to pancreatic cancer, further driving demand for effective treatments. A recent report from S&S Insider said that the Pancreatic Cancer Treatment Market size is expected to reach USD 10.53 billion by 2032 and grow at a CAGR of 15.85%. The report continued: “On the supply side, pharmaceutical companies are actively involved in research and development… Moreover, 322 studies were under clinical trial according to clinicaltrail.com in their 3, and 4 phases. Governments also play a crucial role with increased funding for research initiatives and streamlined regulatory processes can accelerate the development and approval of new treatments. Collaborations between public and private entities foster progress, with the shared goal of improving patient outcomes. The overall market for pancreatic cancer treatments is expected to experience significant growth due to the increasing prevalence of the disease and the ongoing search for effective therapies. The development of innovative approaches… offers hope for patients and presents opportunities for pharmaceutical companies and research institutions.” Active biotech and pharma companies in the markets this week include Oncolytics Biotech® Inc. (NASDAQONCY) (TSX: ONC), GSK plc NYSE: GSKNYSEGSK)(NASDAQ: AZNNASDAQAZN, Gilead Sciences, Inc. (NASDAQ: GILDNASDAQ), Bristol Myers Squibb (NYSE: BMYBMY).
Gilead Sciences, Inc. (Nasdaq: GILD) and LEO Pharma today announced a strategic partnership to accelerate the development and commercialization of LEO Pharma’s small molecule oral STAT6 (signal transducer and activator of transcription 6) programs for the potential treatment of patients with inflammatory diseases.
Galapagos NV plans to split into two entities by mid-2025, focusing on oncology cell therapy and innovative medicines, with €2.45 billion allocated to SpinCo's pipeline.
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb.
(BPT) - The summer spike in COVID-19 infections, triggered in part by a rise in new variants of the virus, was an unpleasant reminder that COVID-19 is here to stay. As we brace for an anticipated larger wave of COVID-19 cases during the fall and winter respiratory season, healthcare professionals want to remind the public that the virus does not affect everyone equally; some people, because of their age or overall health, may be at greater risk for severe illness.1,2
Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) whose disease has progressed on or after platinum-based chemotherapy.
Gilead Sciences, Inc. (Nasdaq: GILD) and Terray Therapeutics, Inc. announced today that the companies have entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets.
